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Abstract
Schistosomiasis is among the most neglected tropical diseases, since its mode of spreading tends to limit the contamination
to people who are in contact with contaminated waters in endemic countries. Here we report the in vitro and in vivo anti-
schistosomal activities of trioxaquines. These hybrid molecules are highly active on the larval forms of the worms and
exhibit different modes of action, not only the alkylation of heme. The synergy observed with praziquantel on infected mice
is in favor of the development of these trioxaquines as potential anti-schistosomal agents.
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Introduction
Malaria and schistosomiasis are the two most important
parasitic diseases in tropical and sub-tropical areas. The parasite
species responsible of these diseases are quite different: Plasmodium
is an intracellular protozoa while Schistosoma is a metazoan worm.
However these parasites share a common feature, they are both
hematophagous. During their development in human blood
stream, they digest a large quantity of host hemoglobin. As a
consequence of the proteolytic digestion of this heme-containing
protein, free heme is released and constitutes a major threat for
both parasites due to its easy reduction by endogenous electron
sources. The iron chelated by the protoporphyrin-IX ligand of
heme is particularly efficient in oxygen reduction by monoelec-
tronic transfer. This catalytic dioxygen reduction is at the origin of
highly toxic reactive oxygen species (ROS). Despite their high
phylogenetic divergence, convergent evolution has conducted
these two parasite species to use a similar heme detoxification
pathway. The hemozoin pigment, known as malaria pigment in
Plasmodium, is an aggregation of heme dimers turning the iron
inactive. Hemozoin is a dark-black inert crystalline pigment, which
is structurally identical in Plasmodium and Schistosoma [1,2].
The treatment and control of schistosomiasis currently rely on
the use of a single drug, the praziquantel (PZQ, Figure 1).
Praziquantel, a safe and effective drug, has been used for the last
fourty years. However, several schistosome strains with lower
sensitivity to praziquantel with possibility of resistance have been
identified in African countries [3,4]. Having a single drug to treat a
disease that affects hundred millions of people is a real concern,
due to the possible resistance of the parasite to this drug. As a
consequence, in the last ten years important efforts have been
made in either developing new drug series [5–7a,b], or testing
existing drugs originally used on non-related diseases [8–13].
Among the existing medications, the antimalarial drugs targeting
heme (i.e. before the hemozoin formation) are particularly
interesting since free heme is not present in non-infected persons.
In this field, two major series of molecules can be considered
according their mechanism of action: trioxane-based molecules,
that are heme-alkylating agents [14–17], and aminoquinoline-
based molecules, that are heme-stacking agents [18,19]. Trioxane-
based molecules, whether naturally extracted or chemically
synthesized, have shown moderate anti-schistosomal activities
[10–11]. Similarly, aminoquinoline derivatives have been shown
to be efficient against schistosomes experimentally infected
animals, e.g. the treatment with mefloquine (MFQ) significantly
reduced the number of eggs [20]. Because schistosomiasis and
malaria are co-endemic in several countries, using an anti-malarial
molecule against schistosomiasis might select drug-resistance in
malaria parasites [8,9]. However, many malaria patients treated
with artemisinin-based combination therapy (ACT) are indeed co-
infected with schistosomes. In fact, a study carried out in Co ˆte-
d’Ivoire evidenced that children infected with S. haematobium,
treated with mefloquine-artesunate administered in accordance
with the currently recommended malaria treatment schedule,
showed significantly higher egg reduction rates compared to
children treated with artesunate (ARTS) or mefloquine alone [21].
The future challenge in the treatment of schistosomiasis may be
not to use native anti-malarial drugs but to develop new drugs
considering the mechanism of action of the anti-malarial
molecules targeting free heme. In these conditions, it might be
useful to develop an anti-schistosomal peroxide-based drug that
will be also active against malaria parasites, with the requirement
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resistant strains of Plasmodium. This strategy should provide new
molecules active on both parasites with limited side effects.
Trioxaquines (TXQ) are hybrid drugs containing two pharma-
cophores within a single molecule: a 1,2,4-trioxane and a 4-
aminoquinoline [22]. Initially developed against malaria, they
exhibit a dual mode of action: alkylation of heme with the trioxane
entity, and stacking with heme due to the aminoquinoline moiety,
leading to inhibition of hemozoin formation in vitro [23–25]. As
reported for artemisinin derivatives [14,15], owing to their
trioxane entity, trioxaquines are indeed efficiently activated by
iron(II)-heme, leading to the formation of covalent heme-drug
adducts detected in the spleen of malaria infected mice [16,24].
Because of the relationship of 1,2,4-trioxane-containing drugs with
heme metabolism, we have decided to evaluate the in vitro activity
of trioxaquines on Schistosoma mansoni. Several of these molecules
were found highly active on both larval and mature stages of S.
mansoni [12]. A better understanding of the molecular bases of the
antischistosomal activity of trioxaquines is requested to design new
active drugs, and to optimize the existing drug candidates. As a
confirmation that heme is a general target of drugs active against
blood-feeding parasites, we recently reported that trioxaquine
PA1259 alkylates heme in female adult S. mansoni, and heme-drug
adducts were identified from treated worms [26] (for the structure
of PA1259, see Figure 1). Although important, this feature is
probably not the only mode of action of trioxaquines in
schistosomes. So, we decided to further evaluate their reactivity
toward hemozoin, and also to attempt to have a general picture of
damages induced by trioxaquines in S. mansoni. For this purpose,
the action of a trioxaquine ‘‘prototype’’, PA1259, was compared to
that of three other drugs: the reference drug praziquantel (PZQ),
artemether (ARTM) and mefloquine (MFQ) (Figure 1).
Materials and Methods
1. Ethics Statement
The laboratory has received the permit Nu A 66040 for
experiments on animals from both French ‘‘Ministe `re de
l’Agriculture et de la Pe ˆche’’ and French ‘‘Ministe `re de
l’Enseignement supe ´rieur et de la Recherche’’. Housing, breeding
and animal care of the mice followed the ethical requirements of
our country. The experimenter possesses the official certificate for
animal experimentation delivered by both ministeries (de ´cret nu
87–848 of October 19
th 1987; authorization no 007083). Animal
experimentation follows the guidelines of the French CNRS. The
different protocols used in this study have been validated by the
French veterinary agency. Before parasite infection, mice were
anaesthetized by injection of 0.1 mL/10 g of body weight of a
mixture of Rompun (0.5 mL, 20 mg/mL; Bayer) and Imalge `ne
(1.0 mL, 100 mg/mL; Rho ˆne Me ´rieux) in 8.5 mL of autoclaved
NaCl 8.5 (
o/oo).
2. Parasite and host strains for antischistosomal assays
The host-parasite system used was an albino variety of
Biomphalaria glabrata from Brazil and a strain of Schistosoma mansoni,
also from Brazil, maintained in Swiss CD1 mice (Depre ´, Bourges,
France). Detailed methods for mollusc and mouse infections and
for parasite recovery were previously described [27].
3. In vitro antischistosomal activity
In vitro tests were performed on both free larval (cercariae) and
parasitic stages (schistosomules and adult worms). Cercariae were
recovered in spring water under binocular microscope. Parasitic
stages were recovered after percutaneous infection of mice using
either 120 or 400 parasite cercariae. Mice exposed to 400
cercariae were sacrificed at 21 days after infection for schistoso-
mule recovery, while mice exposed to 120 cercariae were
sacrificed at 49 days after infection for adult recovery. Schistoso-
mules or adult worms, freshly recovered, were washed and placed
in RPMI 1640 medium (supplemented with L-glutamine and
Hepes 25 mM) and store in incubator chamber at 37uC.
Ten to 20 freshly recovered 21day-schistosomules or 49day-
adults were placed in 24-well or in 6-well Falcon plate containing
1 mL or 3 mL of RPMI 1640 medium (supplemented with L-
glutamine and Hepes 25 mM), respectively. Fifty cercariae were
placed in 24-well Falcon plate containing 1 mL of spring water.
The drugs PA1259, PZQ, ART or MFQ were first dissolved in
DMSO to give mother solutions at 100 mg/mL. All further
dilutions were done in DMSO except the last one that was realized
in RPMI 1640 or spring water, for parasitic stage or free larval
stage, respectively. The dilution was complemented with Tween
80 in order to obtain this final ratio dilution: culture medium/
Tween80/DMSO, 1000/0.95/3.8, v/v/v. These drug solutions
were added to Falcon plate that contained worms. The S. mansoni
cultures were then incubated with each drug at final concentration
of 5 or 50 mg/mL for larval stages (cercariae or schistosomules) or
adult stage, respectively (a concentration of 5 mg/mL corresponds
to 10, 16, 17, and 13 mM for PA1259, PZQ, ARTM, and MFQ,
respectively). Control worms were treated with the same culture
medium/Tween 80/DMSO, but without drug. Each test was
performed in duplicate. Every 30 minutes, moving worms were
counted, in order to define the percentage of survivors.
Observation was extended to 8 h. Kaplan-Meier survival analyses
followed by pairwise log-rank tests were used to compare survival
data. Parasites showing no body contractions during a 30-s
observation may be considered dead.
4. In vivo antischistosomal activity
Mice were infected percutaneously with 120 cercariae each.
Twenty-one days (schistosomule stage) or 49 days (adult worm
stage) post-infection, groups of five mice were treated orally. In
monotherapy, PZQ or PA1259 oral treatment was performed
at 100 mg/kg/d for five consecutive days, or at four doses of
Author Summary
Schistosomiasis is a tropical disease affecting more than
200 million people throughout the sub-tropical and
tropical world. The treatment and control of schistosomi-
asis rely on the use of a single drug, the praziquantel and
no vaccine is available. However, schistosome species with
low sensitivity or resistance to praziquantel have been
identified in several countries. It is an urgent need to
develop new drugs against this parasite. In this context,
our study reports the activity the trioxaquine PA1259.
PA1259 is an hybrid drug containing two pharmacophores
within a single molecule: a trioxane and an aminoquino-
line. Initially developed against malaria, the trioxaquines
target the heme a disposal product resulting from the
digestion of the hemoglobin. The first action of the
trioxaquine is an alkylation of the heme with the trioxane
entity, and the second action is stacking with the heme
due to the aminoquinoline moiety. In this study we show
that this new drug is active in vitro against all schistosome
stages (cercariae, schistosomule and adult). The PA1259 is
also active in vivo and shows synergistic action in
association with praziquantel. This opens the route to an
efficient bitherapy of a highly neglected disease.
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9 h). For bitherapy evaluation, treatments were made at the
following PZQ/PA1647 wt/wt ratio: 100/0, 75/25, 50/50, 25/
75, and 0/100. Administration consisted in 4 oral doses of 50 mg/
kg each, given every three hours (total drug dose: 200 mg/kg). In
all cases, control mice were treated with solvent but without drug.
Fifteen days after treatment, mice were killed and worms were
recovered by retrograde perfusion. The viscera were observed to
count the worms in each mouse.
5. ROS production by S. mansoni adult worms following
praziquantel or PA1259 treatment
As a preliminary, the in vitro concentration of PZQ or PA1259
that kills half of the parasites after one hour of incubation (LC50)
was determined (30-secondes immobilized worms were consid-
ered as killed, since no worms recovered an activity after that 30-
sec period of immobilization). For this purpose, the following
ranges of concentrations were tested: 0, 0.01, 0.1, 0.5, 1, 2.5,
5 mg/mL for PZQ, and 0, 5, 10, 20, 30, 40, 50 mg/mL for
PA1259. The incubation medium and drug solvents were as
described above for in vitro treatment of schistosomes. LC50 values
found were 50 mg/mL and 0.075 mg/mL for PA1259 and PZQ
respectively. No difference was observed between male and
female worms.
a. Hydrogen peroxide (H2O2) and superoxide anion (O2N
2)
quantification. Four males and two females of S. mansoni adult
worms were disposed in a 24-well plate with 1 mL of RPMI.
Worms were incubated during one hour with 0.075 mg/mL of
PZQ and 50 mg/mL of PA1259 that correspond to the LC50
values of the drugs. Untreated worms were processed in a same
manner and treated with the excipient. For each drug treatment
and control experiments, ten replicate samples were analyzed.
Drug treated- and untreated worms were washed 3 times with
Krebs-Ringer phosphate buffer (KRPG), sonicated and the total
protein amount were quantified. Fifty mL of supernatant were
disposed in a 96-well plate. Hydrogen peroxide was quantified
with AmplexH Red (50 mL per well, prepared according to the
manufacturer’s instructions). Optic density was measured with a
microplate reader at 570 nm. Superoxide O2
.2 was quantified
with NBT (50 ml of 0.2% NBT (Sigma) dissolved in KRPG per
well). The variation of OD resulting from the formation of
formazan was measured with a microplate reader at 620 nm.
Results were monitored at 0, 10, 20, 30, 45, 60, 90 and
120 minutes and were presented as OD values corrected by
sample protein amount.
Figure 1. Structures of drugs. Praziquantel (PZQ), mefloquine (MFQ), artemether (ARTM), and trioxaquines PA1259 and PA1647.
doi:10.1371/journal.pntd.0001474.g001
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females were disposed in a 24 well plate with 1 mL of RPMI and
treated for 1 h with 0.075 mg/mL of PZQ and 50 mg/mL of
PA1259, respectively. Worms were then washed with RPMI
solution, and NO production was quantified by incubating for one
hour the treated and untreated females with DAF-2DA substrate
(2 mM per well). Then females were disposed on slides and observed
under UV illumination using a LeicaH DMLBH microscope.
Pictures were taken and analyzed by using the imageJ software
[28]. Briefly DAF-2 fluorescence intensity was quantified over the
entire worm surface and results were expressed as mean DAF-2
fluorescent intensity/pixel. For each female picture, mean DAF-2
fluorescent intensity was calculated by separating the Red image
from the Green, and Blue ones (RGB). IndeedRed-image was more
appropriated to calculate fluorescence since DAF-2 fluorescent
background was more attenuated.
6. Chemicals
PA1259 and PA1019, synthetized as reported in the patent
application WO/2007/144487, and PA1647 were provided by
Palumed. PA1647 is the diphosphate salt of PA1259 (stoichiom-
etry checked by CHN-elemental analysis). Artemether (ARTM)
was a gift from Rho ˆne-Poulenc Rohrer Doma (Antony, France).
Praziquantel (PZQ) and mefloquine (MFQ) were purchased from
Sigma-Aldrich, as well as sodium dithionite (Na2S2O4), dimethyl-
sulfoxyde (DMSO, ACS spectrophotometric grade $99.9%),
pyridine ($99%), and methanol (Chromasolv $99.9%). Formic
acid (99+%) was from ACROS. Hemin (ferriprotoporphyrin IX
chloride, 98.0%) from bovine blood was purchased from Fluka
(Switzerland). All chemicals and solvents were used as purchased
without further purification. Milli-Q water (resistivity $18.2 MV)
was used for LC-MS eluent preparation.
7. Extraction of heme and heme-drug adducts from
S. mansoni worms
Adult S. mansoni females were recovered in mice seven weeks
after infection, and maintained in culture in RPMI 1640 medium,
supplemented with L-glutamine and Hepes 25 mM, at 37uC.
Groups of twenty-five schistosomes, freshly recovered, were
carefully washed with RPMI 1640 medium, then treated with
PA1259 or ARTM at 50 mg/mL for 3 hours. Then, worms were
crushed with sand, and the obtained powder was extracted with
pyridine (500 mL). The mixture was vigorously stirred (vortex),
placed in an ultrasonic bath for 30 min and, finally, magnetically
stirred at 37uC overnight. After centrifugation at 4000 rpm for
30 min, the supernatant was withdrawn and filtered through ptfe
0.45 mm syringe filters before analysis by HPLC or LC-MS.
8. LC-MS analysis
a. HPLC conditions for heme-drug adducts. The LC-MS
analyses were performed using a Agilent 6140 equipment (HPLC
column: 5 mm C18 X-Bridge, 15064.6 mm, Waters; linear elution
gradient from water/formic acid, 100/1, v/v to methanol/formic
acid, 100/1, v/v in 30 min; flow rate=1 mL6min
21; injection
volume: 100 mL; UV-vis. detection at 398 nm (lmax of heme), and
ESI
+-MS detection). The analytic conditions were previously
optimized by using chemically prepared heme-PA1259 adducts
[3.2 mg of Fe
III(PPIX)Cl, 10 molar equivalent of sodium dithionite
and 1.5 molar equivalent of trioxaquine PA1259 were dissolved in
500 mL DMSO. The reaction was carried out at 37uC, under an
argon atmosphere, for 2 h].
b. Mass spectrometry conditions. The ionization was
performed in electrospray mode, using an Agilent 6410 triple
quadrupole setup (source temperature =350uC, gas flow nebulizer
=13L.min
21). The detection and quantification were performed in
scanning mode (total ionic current) with a step size of 0.1 atomic
mass units (amu) and scan range of 300–1200 amu.
9. Electronic Microscopy
a. Scanning electron microscopy (SEM). Schistosomes
were fixed with 2% glutaraldehyde in Sorensen buffer (0.1 M,
pH=7.4) for 1 hour, washed with cacodylate buffer (0.1 M
sodium cacodylate) for 12 hours. After dehydration and critical
point drying, they were mounted on microscope stubs, followed by
platinum sputtering during 160 seconds. We used a SEM-FEG
microscope (JEOL JSM 6700F) with an accelerating voltage of
30 kV. The head of schistosomes was first located, and
photographs were then recorded, with magnification 61000,
62000, or 65000 (50 photographs per worm; two worms for each
treatment).
b.Transmissionelectronmicroscopy(TEM). Schistosomes
were fixed with 2% glutaraldehyde in Sorensen buffer (0.1 M,
pH=7.4) for 1 hour, washed with the same buffer for 12 hours.
They were postfixed with 1% OsO4 in Sorensen buffer 0.05 M and
saccharose 0.25 M for 1 hour. Schistosomes were dehydrated by
incubation in successive aqueous ethanol solutions containing an
increasing proportion of ethanol up to 100 vol%, and then
embedded in LR Whyte resin (medium grade acrylic resin,
Electron Microscopy Sciences). After 48 h of polymerization at
220uC under UV irradiation, ultrathin sections (50 nm) were
mounted on 150 mesh collodion-coated copper grids and
poststained with 3% uranyl acetate in 50% ethanol, and with
8.5% lead citrate, before being examined on a HU12A Hitachi
electron microscope, at an accelerating voltage of 75 kV.
c. X-ray analysis. The presence of iron in hemozoin pellets
was assessed by using a TEM-FEG (JEOL JEM 2100F) electronic
microscope, with an accelerating voltage of 200 kV, equipped with
an element analyzer (PGT, resolution 136 eV). This analysis has
been performed on the ultrathin sections of schistosomes
previously analyzed by TEM.
Results
1. In vitro activity of trioxaquine PA1259 on free and
parasitic stages of S. mansoni
The in vitro activities of PA1259 (&), praziquantel (w),
artemether (X), and mefloquine (N
) on cercaria-, 21 day-old
schistosomules, and 49 day-old adult worms are reported in
Figure 2A, 2B, and 2C, respectively, as Kaplan-Meier plots. When
treated with PZQ at 5 mg/mL, after 4 h of contact with the drug,
all cercaria were immobilized for a 30 s-observation time. To
obtain such immobility after treatment with PA1259 or MFQ
required only 60 or 90 min, respectively. In the presence of
ARTM, 8 h after treatment, more than 80% of cercariae were still
moving (Figure 2A). The treatment of 21-day schistosomules with
PZQ at 5 mg/mL resulted in a complete immobilization of all
larvae after 3 h of contact. With PA1259 or MFQ, the same effect
was obtained after 5 h and 8 h, respectively. When ARTM was
used in the same conditions, no significant effect was observed
after 8 h (Figure 2B). The treatment of 49-day adult schistosomes
with drugs at 50 mg/mL resulted in complete immobilization of all
worms in 2 h in the presence of PZQ, and 3 h in the presence of
MFQ or PA1259. With ARTM at the same concentration, more
than 60% of worms were still moving after 8 h (Figure 2C).
In addition, the activity of PA1019, which is the 4-aminoquino-
line residue contained in PA1259, was evaluated on schistosomules
and adult worms. Seven hours of contact of PA1019 was required
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worms.
2. Activity of trioxaquine PA1259 on mice infected by
S. mansoni
In mice infected by S. mansoni, the reduction of worm burden
upon oral treatment by PA1259 or PZQ is reported in Table 1. In
mice treated with PA1259 at five daily doses of 100 mg/kg starting
from day 21 post-infection, 26.665.4 worms were collected 15
days later. When treatment was done at day 49 post-infection,
21.067.0 worms were collected. These values correspond to a
reduction of 31% and 42% on larval and adult stage, respectively,
with respect to mice treated by excipient alone (control mice).
With the same treatment schedule, PZQ induced a worm burden
reduction of 20% and 79% on schistosomules and adult worms,
respectively. With four doses of 50 mg/kg of PA1259 given every
three hours, the reduction of the worm burden was 53%
(16.867.2 worms) or 40% (20.065.1 worms) on larval stage or
adult stages, respectively. The same treatment schedule but with
PZQ induced a worm burden reduction of 41% and 86% on
schistosomules and adult worms, respectively. These treatments
did not induce any visible adverse effect in mice.
3. Trioxaquine - praziquantel association on mice
infected by S. mansoni schistosomules
The effect of a combination of PZQ and trioxaquine PA1647 on
the reduction of the worm burden in S. mansoni infected mice is
reported in Table 2. The first course consisted of 4 oral treatments
with 50 mg/kg of drug given every three hours. The drug
combinations were 100% of PZQ (line 2), 75 wt% PZQ/25 wt%
PA1647 (line 3), 50 wt% PZQ/50 wt% PA1647 (line 4), 25 wt%
PZQ/75 wt% PA1647 (line 5), and 100% of PA1647 (line 6),
respectively. In these conditions, the reduction of the schistoso-
mules burden with respect to control mice was 24% with 100%
PZQ (line 2), 73% with 75 wt% PZQ/25 wt% PA1647, (line 4),
and 18% with 100% of PA1647 (lines 2, 4, and 6, respectively).
These treatments did not induce any visible adverse effect in mice.
4. Microscopy
Adult S. mansoni females were treated in vitro with PA1259, PZQ,
ARTM or MFQ at 50 mg/mL for three hours, and compared with
untreated worms (excipient only).
a. Photon microscopy. Upon treatment with trioxaquine
PA1259 at 50 mg/mL, a brown cloud of small dark crystals readily
appeared in the culture medium (right part of the Figure 3A). Few
minutes after treatment, the black color inside the gut of worms
(Figure 3D and 3E, untreated worms) turned to light brown
(Figure 3B). After one hour, the gut walls of treated worms were no
more visible, and the brown pigment invaded the whole worm
body (Figure 3C). Such a modification was observed with none of
the reference drugs, namely PZQ, ARTM, or MFQ.
b. Scanning electron microscopy (SEM). First of all, the
general morphology of worms was rather affected, especially after
treatment with mefloquine or trioxaquine PA1259 (Figure S1).
Worms treated with PA1259 were convoluted (Figures 3C and
S1c). The schistosomes treated by mefloquine seemed stiff,
contracted (with a mean diameter significantly reduced with
respect to untreated, Figure S1d). Worms treated with PZQ
exhibited local drastic swelling (encircled zone in Figure S1b). In
some cases, the breaking of the worm occurred during the
preparation for microscopy. These events, not related to the drug
treatment, are indicated as white crosses in Figure S1.
Second, chistosomes exhibit spines along all the length of body,
but with a higher density in the hindbody and forebody parts with
respect to midbody part, and on the dorsal side with respect to the
ventral one (Figure S7). The ciliated sensory papillae were also well
visible. The treatment with trioxaquine PA1259 induced a drastic
disorganization of spines, which became rough and bushy (Figure
S2c). In some places, the disappearance of spines, along with
dilated spine sockets, was observed, suggesting that spines have
been drawn back (Figure S3c). The spines were nearly unchanged
upon treatment with PZQ or ARTM (Figure S2, panels b and e,
Figure 2. Comparative In vitro activities. PA1259 (&), praziquantel
(w), artemether (X), and mefloquine (N) on cercariae (A), on 21-days
old schistosomules (B) and on 49-days old adult (C) S. mansoni. Cultured
larvae (cercariae or schistosomules) or adults were treated with
compounds at 5 mg/ml or 50 mg/ml, respectively.
doi:10.1371/journal.pntd.0001474.g002
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that became subsided, losing their domed shape and their sensory
cilium (arrows in Figure S2b and Figure S3b). Extensive blistering
occurred with ARTM (arrows in Figure S3e). Treatment with
MFQ induced a cavernous aspect of the worm, with disappear-
ance of spines, and complete destruction of the external structures
(Figure S2d).
Third, the tegument of control schistosomes exhibited normal
circular ridges with regular clefts (Figure 4a). After treatment with
PZQ or trioxaquine PA1259, the transverse tegumental ridges
encircling the body worm were not observable any longer.
Swelling induced loosing of the clefts, and fusions of ridges were
always observed (Figure 4, panels b and c, respectively, and S4).
Ridges were damaged, but still visible after treatment by
artemether (Figure 4e and S4e), in contrast to females treated
with praziquantel or PA1259, which showed a complete fusion of
the ridges. PZQ mainly induced swelling and formation of holes,
probably corresponding to damaged sensory papillae (arrow in
Figure S3b). In the case of PA1259, the fusion of ridges was
accompanied by formation of long irregular and disorganized
splits (arrows in Figure S4c). Worms treated with PA1259 were
also characterized by swelling, and dilated and/or empty spine
sockets were visible (Figure S3c). After treatment with artemether,
there were both rather undamaged regions, with well-conserved
ridges and regions showing extensive vesiculations, burst of blebs,
erosion of the tegument and sloughing (Figures 4e and S3e). The
extensive blistering observed upon treatment with artemether was
not present with the other drugs. Blebs were so large that they
fused together, inducing a detachment of large parts of the
tegument layer, and splits parallel to the ridges. Magnification of
this peeling phenomenon is depicted in Figure S5b, and compared
with erosion and peeling subsequent to PA1259 treatment (Figure
S5a). In the latter case, focal sloughing was also present, but no
rest of the tegumental layer could be observed. After ARTM
treatment, round holes, about 1 mm large, were also visible in the
underlying layer (Figure S5b). MFQ treatment induced the most
destructive damages with a cavernous aspect of worm surfaces
(Figures 4d and S4d). In addition, whether the treatment, the oral
and ventral suckers were affected in most of the worms examined,
showing serious deformations and extensive swelling (data not
shown).
c. Transmission electron microscopy of S. mansoni
(TEM). By ultramicrotomy, ultrathin (50 nm) transverse
sections of S. mansoni adult females were prepared. For each
drug treatment, three worms were analyzed by TEM (four sections
prepared for each worm).
First, the hemozoin pellets appeared as 200–300 nm large
contrasted dark grey disks. Early crystallization of hemozoin was
visualized at the surface of lipid droplets giving dark grey circles
with light grey inside [29]. The presence of iron was assessed by
energy dispersive (X-ray) microscopy in mature- or in formation-
hemozoin pellets (noted 3 and 2, respectively, in Figure 5a). By
Table 1. In vivo effect of PA1259 and praziquantel.
Treatment Administration Schistosomula Adult
Mean number of worms ± SD Worm reduction Mean number of worms ± SD Worm reduction
Control 38.665.4 _ 33.465.0 _
PA1259 56100 mg/kg
a 26.665.3 31%* 21.067.0 42%*
PZQ 56100 mg/kg
a 30.762.4 20% 7.467.8 79%*
Control 35.465.0 _ 33.465.0 _
PA1259 4650 mg/kg
b 16.867.2 53%* 20.065.1 40%*
PZQ 4650 mg/kg
b 21.066.0 41%* 4.866.5 86%*
Effect on worm recovery of two administration protocols of PA1259 and praziquantel (PZQ) administered to mice harbouring either a 21-day-old schistosomula or 49-
day-old adult S. mansoni infection.
aThe five doses of 100 mg/kg were administered daily during five consecutive days.
bThe four doses of 50 mg/kg were administered every three hours (overall treatment period: 9 h).
*Significant difference compared to the control group at 5% level (Mann-Whitney U test). SD stands for standard deviation.
doi:10.1371/journal.pntd.0001474.t001
Table 2. In vivo effect of PA1647 combined with praziquantel on 21-day-old schistosomula.
21-day Schistosomula
Treatment Mean number of worms ± SD Worm reduction
1 Control (excipient alone) 43.464.9 _
24 6(PZQ 50 mg/kg) 33.061.6 24%
34 6(PZQ 37.5 mg/kg + PA1647 12.5 mg/kg) 31.062.7 29%
44 6(PZQ 25 mg/kg + PA1647 25 mg/kg) 11.663.9 73%*
54 6(PZQ 12.5 mg/kg + PA1647 37.5 mg/kg) 31.563.1 27%
64 6(PA1647 50 mg/kg) 35.864.4 18%
The treatment schedule consisted in four doses of 50 mg/kg (sum of the two drugs) every three hours.
*Significant difference compared to the control group at 5% level (Mann-Whitney U test). SD stands for standard deviation.
doi:10.1371/journal.pntd.0001474.t002
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(noted 1 in Figure 5a).
Images obtained for control worms, compared with those
obtained after treatment with mefloquine (MFQ), praziquantel
(PZQ), and trioxaquine PA1259 are depicted in Figure 6. The gut
of S. mansoni adult females treated with PA1259 (panel d) exhibited
a drastically lower hemozoin content with respect to control
worms (panel a). Upon treatment with MFQ or PZQ, the
hemozoin content was significantly reduced with respect to control
worms (panels b and c, respectively), but in much lower proportion
than upon treatment with PA1259. In addition, upon treatment by
PA1259, a part of remaining hemozoin pellets migrated across the
epithelium and was found lining its external membrane (Figure 6,
panels e and f).
Second, the vitelline cells of control female worms were well
characterized (Figure S6a). Ultrastructure of vitelline cells of
worms treated with PZQ and ARTM exhibited focal fusion of
vitelline balls in vitelline droplets (vd on Figure S6, panels b and e,
respectively). However, the most part of vitelline cells remained
intact. By contrast, extensive alterations appeared in schistosomes
treated with PA1259 and, in a greater extent with MFQ (panels c
and d, respectively). Fusion in the process of vitelline balls (arrows
on Figure S6, panel c1), and formation of lipid droplets were seen
(ld in panel d2).
Third, the tegumental matrix (t), spine and spine sockets (s), and
muscle bundles (m) were clearly visible on many transmission
electron micrographs of control worms (Figure 7, panels a). After
treatment with PZQ, the extent of tegumental damages was
significantly different depending on the parasite sections. Howev-
er, in the most part of cases, the tegumental matrix was slightly
modified, but significant swelling of the underlying muscle bundles
occurred (Figure 7, panels b). Treatment with PA1259 (Figure 7,
panels c) caused complete disappearance of the tegument matrix
and severe swelling and disorganization of the sub-tegumental
muscle layer (m). Some spines were still visible (s). The severity of
tegumental damages induced by treatment with MFQ are visible
in Figure 7d. All the worm sections exhibited complete lysis of
tegument, extensive disappearance of spines, and collapse of
internal structures. ARTM induced deep clefts in the tegument,
but the damages were drastically less important than those caused
by PA1259 or MFQ (Figure 7, panels e).
5. Molecular mechanism of damages induced by
antischistosomal drugs
a. Reduced or radical oxygen species: NON,O 2N
2,
H2O2. Dosage of reduced oxygen species O2N
2,H 2O2, and
NON, is reported in pannels A, B, and C of Figure 8, respectively.
In worms treated with PZQ, the production of O2N
2 was roughly
twice higher than that of control worms (Figure 8A: PZQ (&):
OD=0.0075, Control (X): 0.0041). By contrast, treatment with
PA1259 (m, OD=0.0031) did not improve the production of
O2N
2 with respect to control. The production of H2O2 whether
control, PZQ, or PA1259 treated worm, was not significantly
different (optic density values being 0.0017, 0.0019, and 0.0016 for
control (X), PZQ (&), and PA1259 (m)-treated worms,
respectively; Figure 8B). The production of NON was very low in
control worms (Figure 8, panel C1, intensity 44614, pannel C4).
Females treated with PZQ exhibited a slightly enhanced
fluorescence due to NON located near the tegument (Figure 8,
panel C2, intensity 67616, pannel C4), whereas, in females
treated with PA1259, the fluorescence due to NON was very high,
and mainly detected inside the gut and near the vitelline cells
(Figure 8, panel C4 and C3, respectively, intensity 190643, panel
C5).
b. Characterization of covalent heme-drug adducts. The
LC-MS profile of the extract of worms treated by ARTM is
depicted in Figure 9. Chromatographic peaks with retention times
28.8, 29.4, and 29.9 min exhibited an intense ionic current with
Figure 3. Optic microscopy of treated worms. S. mansoni females treated with PA1259 at 50 mg/mL (A, C, and E), compared to control worms (B
and D). Hz stands for hemozoin. In B and D: black Hz in a well defined gut; in C: Few minutes after treatment, Hz turns to brown inside the gut; in E)
one hour after treatment the brown pigment was transfered outside of the gut.
doi:10.1371/journal.pntd.0001474.g003
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praziquantel (PZQ), c) trioxaquine PA1259, d) mefloquine (MFQ), or e) artemether (ARTM). Magnification61000 (a1-e1),62000 (a2-e2),65000 (a3-e3);
the bars stand for 10 mm.
doi:10.1371/journal.pntd.0001474.g004
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picture (a): b1. Background: low contrasted zone, b2. Hemozoin pellets in early stage formation, b3. Hemozoin pellets at final stage.
doi:10.1371/journal.pntd.0001474.g005
Figure 6. TEM images of hemozoin (Hz) inside the gut. Control worms (a), compared to worms treated with b) mefloquine (MFQ), c)
praziquantel (PZQ) or d, e, f) trioxaquine PA1259, and g) artemether. The scale bars stand for 2 mm in panels a, b, c, d, f, and g, and for 5 mm in panel e.
doi:10.1371/journal.pntd.0001474.g006
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of a compound having m/z=936.4 amu was also detected
(compound 1, Figure 9b).
The LC-MS analyses of extracts of S. mansoni worms treated
with PA1259 are reported in Figure 10a-c. Along with the ionic
current of heme [Rt=26.1 min, m/z=616.2, z=1, M
+ for
Fe
III(PPIX), Figure 10a], several chromatographic peaks were
detected at Rt=24.7, 25.3, 26.3, and 26.5 min, with m/z=551.3
and z=2, having an exact mass value of 1101.2 amu (Compounds
3, 4, Figure 10b). Another product 5 was also detected (Rt=25.1
and 25.7 min, m/z=730.3, z=1, Figure 10c).
c. Heme oxidative cleavage in S. mansoni. Twenty five
freshly recovered S. mansoni adults were maintained in RPMI for
3 h, but without drug treatment, and then extracted with pyridine
as described above. The LC-MS analysis of the extract exhibited
the presence of two chromatographic peaks with the same m/z
value of 347.1 amu (Rt=13.8 and 14.1 min). We failed to detect a
significant amount of these compounds in schistosomes treated
with ARTM or MFQ under similar conditions.
Discussion
1. In vitro activity of trioxaquine PA1259 on free and
parasitic stages of S. mansoni
The in vitro activities of PA1259 (&) on cercariae, schistoso-
mules, and adult worms S. mansoni are reported in Figure 2A, 2B,
and 2C, respectively, along with activities of praziquantel (w),
artemether (X), and mefloquine (N
) given as comparison. Results
depicted in Figure 2 show that PA1259 exhibits a significant anti-
schistosomal activity on all parasite stages. Concerning the free
cercarial stages, PA1259 and MFQ have similar efficacy (all
cercariae were dead within 60–90 min, Figure 2A). These two
drugs are significantly more efficacious than PZQ (after 90 min of
treatment with PZQ, 80% of cercariae were still moving, and
Figure 7. TEM images of tegument. Control worms (a), compared to worms treated with b) praziquantel (PZQ), c) trioxaquine PA1259, d)
mefloquine (MFQ), or e) artemether (ARTM). The scale bars stand for 2 mm in panels a1-e1, and for 1 mm in panels a2-e2.
doi:10.1371/journal.pntd.0001474.g007
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schistosomules stage, the time required to kill all schistosomules
was 3 h, 5 h, or 8 h, with PZQ, PA1259, or MFQ, respectively
(Figure 2B). So, PZQ and PA1259 are more active than MFQ. On
adult parasites, the activities of these three last molecules are not
significantly different (p.0.05), with all worms killed at 2–3 h
(Figure 2C). The in vitro activities obtained for both MFQ and
PZQ are consistent with previous reports [30,31]. Compared to
MFQ, PA1259 is more potent on schistosomule stage, and has the
same activity on adult stage. It is noteworthy that MFQ, based on
a quinoline moiety, is active on the cercarial stage, whereas
ARTM, containing a trioxane, is not. This feature suggests that
the quinoline part of PA1259 may play a role in its activity against
schistosomes (especially the cercarial stage), and that the parasite
heme is not the only target of this drug (cercariae do not contain
heme). In fact, a non-heme target has recently been proposed for
MFQ [30]. ARTM is inactive on cercariae and schistosomules,
and only poorly active on adult worms. In fact, this latter drug was
reported to be active only when hemin was added in the culture
medium [32].
In addition, the activity of PA1259 on schistosomules and adult
worms was compared with that of PA1019 which is the 4-
aminoquinoline residue contained in PA1259 (see Figure 1 for the
structure of PA1019). PA1019 was only poorly active, and 7 h
were required to immobilize only 27% of schistosomules and 79%
of adult worms. By contrast, treatment with PA1259 immobilized
100% of schistosomules and adult worms after 5 h or 3 h,
respectively. This result support an additive or synergistic effect of
the quinoline and trioxane moieties of PA1259.
2. Activity of trioxaquine PA1259 on mice infected by
S. mansoni
In S. mansoni mice, the reduction of worm burden upon oral
treatment by PA1259 or PZQ is reported in Table 1. The
administration of trioxaquine PA1259 at five daily doses of
100 mg/kg resulted in a reduction of 31% and 42% on larval and
adult stage, respectively. With four doses of 50 mg/kg every three
hours, the reduction of worm burden was 53% or 40% on larval or
adult stages, respectively. Whatever the used protocol, the activity
of PA1259 on larval stage was very close (slightly higher) to that of
PZQ. On adult stage, PA1259 exhibited a significant activity, with
a reduction of the worm burden being half of that obtained with
PZQ. It is noteworthy that the efficacy of PA1259 was very close
on schistosomules and adult worms, whereas PZQ exhibited a
significantly higher efficacy on adult schistosomes compared to
schistosomules. This feature suggests a different mode of action for
these two drugs. For comparison purpose, quinoline- or artemi-
sinin-based molecules present variable efficacy. For instance,
among quinoline-based molecules, MFQ exhibits a significant
efficacy against schistosome infections, but chloroquine is inactive
against schistosome infections [8]. For comparison, artemisinin
derivatives or synthethic trioxolanes mainly possess activity against
schistosomules [33,34]. In a mouse model, ARTM was reported to
be inactive at 800 mg/kg on adult S. mansoni infection [33].
In addition, on S. mansoni schistosomules, 4 doses of 50 mg/kg of
PA1259 every three hours (total dose of 200 mg/kg given over a
period 9 hours) was found to be a more efficacious protocol than a
total dose of 500 mg/kg given over a period of 5 days (100 mg/kg
administered daily).
Figure 9. LC-MS analysis of the extract of Schistosoma mansoni
treated with artemether (50 mg/mL). Extracted ionic current (EIC)
traces for: (a) m/z=616.2 (Heme, M
+); (b) m/z=936.4 (‘‘Complete’’
heme-artemether adduct 1, (M-H+Na)
+; (c) m/z=854.4 (heme-arte-
mether adduct 2,M H
+). (Inserts correspond to the mass spectra of
circled chromatographic peaks).
doi:10.1371/journal.pntd.0001474.g009
Figure 10. LC-MS analysis of the extract of Schistosoma mansoni
treated with trioxaquine PA1259 (50 mg/mL). Extracted ionic
current (EIC) traces for: (a) m/z=616.2 (Heme, M
+); (b) m/z=551.3
(‘‘Complete’’ heme-PA1259 adducts 3 and/or 4,M H
+/2); (c) m/z=730.3
(heme-PA1259 adduct 5,M H
+). (Inserts correspond to the mass spectra
of chromatographic peaks with arrows).
doi:10.1371/journal.pntd.0001474.g010
Figure 8. Reduced or radicals oxygen species dosage. A. Superoxide anion (O2N
2) was dosed using Nitro Blue Tetrazolium method B.
Hydrogen peroxide (H2O2) was dosed using Amplex Red method. B. Nitric Oxide (NON) was dosed using DAF-2 method.
doi:10.1371/journal.pntd.0001474.g008
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infected by S. mansoni schistosomules
Owing to the complementarity of PZQ and trioxane based
drugs against schistosomes, we investigated the reduction of the
worm burden in mice infected by 21-day S. mansoni schistosomules
when orally treated with an association of PZQ and trioxaquine
PA1647, the diphosphate salt of PA1259 (Figure 1). Five courses
were done with different proportions of PZQ and PA1647. Each
course consisted of four oral doses of (PZQ + PA1647), at a total
amount of 50 mg/kg for each dose (Table 2). The reduction of the
schistosomule burden with respect to control mice was 73% with
50 wt% PZQ/50 wt% PA1647, (corresponding to 32 mol% of
PA1647, line 4). For comparison, it was only 24% or 18% when
PZQ or PA1647, respectively, were used as monotherapy (lines 2
and 6, respectively). A simple additive effect between PZQ (24%
worm burden reduction at 50 mg/kg), and PA1647 (18% worm
burden reduction at 50 mg/kg) would have provided at best a
(24+18)/2=21% worm reduction with the combination PZQ
25 mg/kg + PA1647 25 mg/kg. In fact, such a combination
resulted in a significantly higher reduction of 73% (line 4). So, the
results are consistent with an additive or synergistic effect against
schistosomules.
Then, due to this promising effect of PZQ and PA1647 on
schistosomules, the PZQ/PA1647 association should be consid-
ered as a drug-association candidate for future clinical tests, after
additional optimization on the association drug ratio, in order to
target all parasite stages.
4. Microscopy
Adult S. mansoni females were treated in vitro with PA1259,
praziquantel, artemether or mefloquine were examined by
photon- and electron microscopy (SEM and TEM), with special
focus on hemozoin, vitelline cells, musculature and tegument. In
all cases, morphological alterations were apparent, but in highly
variable extent and nature. The main observations reported in the
Result Section were summarized in Table 3 where the most
specific results have been indicated in bold. The following points
are worth being emphasized.
a. Photon microscopy. Upon treatment by trioxaquine
PA1259, adult females schistosomes readily regurgitated
hemozoin, which is visible as a brown ‘‘cloud’’ in the right part
of the Figure 3A. Few minutes after treatment, the remaining Hz,
which was black in control worms (Figure 3D and 3E), turned to
light brown color inside the gut of the treated worms (Figure 3B).
Some time later, the gut walls of treated worms were no more
visible, and the brown pigment invaded the whole worm body
(Figure 3C). Such a modification was observed with none of the
reference drugs, namely PZQ, ARTM, or MFQ. It strongly
suggests that hemozoin is one of the targets of PA1259.
b. Scanning electron microscopy (SEM). The tegument of
trematodes is usually considered for its key role in nutrient
absorption [33], secretory functions [34], and parasite protection
against the host immune system [35]. Tegument is considered as
the target (or one of the targets) of PZQ because it was shown by
SEM that the biologically active levo-PZQ enantiomer was more
prone to induce tegumental damages in S. mansoni than dextro-
PZQ [36].
Worms treated with PA1259 were convoluted (Figures 3C and
S1c). In fact, during the antischistosomal evaluation of trioxaquines,
we have tested 90 trioxaquines (partial results have been reported in
reference 12). With all active drugs of this series, the female S.
mansoni worms adopted the shape of a loosen knot. It was so general,
that it was possible to use this fact to detect trioxaquine-treated
worms in blind assays [Boissier and Portela, unpublished work].
The disorganization of spines and the dilated spine sockets
induced by PA1259 (Figure S2c and S3c, respectively) might be
due to damages of the subjacent musculature of these retractile
structures.
It should be noted that tegumental erosion and peeling upon in
vitro treatment of S. mekongi [37] or in vivo treatment of other
trematode parasite, such as Clonorchis sinensis [38], or Fasciola
hepatica [39] by ARTM have been reported in the recent years.
Severe deformations of the tegument surface were seen in many
worms, resulting in significant changes of the overall morphology
of the worms. These facts suggest a drastic effect of drugs not only
on the external tegument matrix, but also on the subjacent
structures such as worm musculature. The observation of damages
on a given part of the worms, namely hemozoin, tegument or
suckers does not indicate that such a part of the worm is the
location of the main target of the drug, even less the only drug
target. Indirect widespread damages are indeed expected upon
treatment in lethal conditions. However, we observed a significant
number of differences between the damages induced by PZQ,
ARTM, MFQ and PA1259, which are probably related to
different mechanisms of action for these different drugs.
c. Transmission electron microscopy (TEM). Beyond the
general morphology and aspect of S. mansoni external structures,
we examined the effect of the different drugs under a transmission
electron microscope of ultrathin transverse sections of
schistosomes. If the SEM study of trematode parasites has been
well documented in literature, transmission-electron microscopy
(TEM) studies are less common [40,41].
Upon treatment with PA1259, MFQ or PZQ, the hemozoin
content was significantly reduced with respect to control worms
(Figure 6). A semi-quantitative estimation was carried out by
counting the number of hemozoin pellets on a total surface of 200–
300 mm
2 in the mid-body region. The mean number of hemozoin
pellets per mm
2 was 1.6 for control schistosomes, 1.2 after treatment
with ARTM, 0.8 and 0.6 after treatment with MFQ and PZQ,
respectively, and close to 0.1after treatment with PA1259.Then the
gut hemozoin content of schistosomes treated by PA1259 was about
10% of that of untreated schistosomes. In addition, upon treatment
by PA1259, a part of remaining hemozoin pellets was found lining
the external epithelium membrane (Figure 6, panels e and f),
suggesting perforation of the gut epithelium. However, the total
hemozoin content in the gut lumen and epithelium was 0.2 pellet
per mm
2 after treatment with PA1259.
After treatment with PZQ, the tegumental matrix was slightly
modified, but significant swelling of the underlying muscle bundles
occurred (Figure 7, panels b). This feature argues that a main PZQ
target should be musculature, instead of tegument, as previously
reported [42]. TEM micrographs of worms treated by PA1259
exhibited complete disappearance of the tegument and severe
swelling and disorganization of the sub-tegumental muscle
(Figure 7, panels c). These images should be linked to SEM
Table 3. Relative intensity of damages on cultured S.
mansoni, observed by electron microscopy.
Treatment PZQ PA1259 MFQ ARTM
Target Hemozoin ++ + ++++ ++ +
Vitelline cells ++ + + +++ +
Tegument + +++ +++ + ++
Musculature +++ +++ +++ -
doi:10.1371/journal.pntd.0001474.t003
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into spine sockets, and extensive erosion of the tegument (Figure
S3c and S5, respectively).
MFQ and PA1259 were the two drugs inducing the most severe
damages to the tegument. These modifications may lead to
exposure of worm surface antigen, resulting in attack of the
parasite by host immune system. This fact had to be confirmed by
investigation of the molecular processes responsible for the
morphologic damages.
In previous reports, decrease of hemozoin gut content, as well as
gut epithelium alteration, was observed in S. mansoni worms treated
with quinine [43]. However, the authors did not observed
alteration of tegument after quinine treatment. Extensive tegu-
mental damage has been observed in both male and female worms
treated with MFQ [29,44]. Similar observations were obtained
with S. japonicum parasite treated with MFQ [45]. Almost the same
observations, (i) damage of tegumental and subtegumental
structures, (ii) alteration of gut epithelial cells and (iii) fusion of
vitelline balls were obtained in S. mansoni worms treated with
artemether [46], but in a lower extent. Despite some common
effects of drugs targeting heme, whatever their structural origins,
trioxane-based, aminoquinoline-based or hybrid molecules
(PA1259), on schistosomes, it is clear that the intensity of the
effect and the morphological aspect after treatment vary according
to the drug itself.
Upon treatment with PZQ, the most important damages were
observed on the musculature of schistosomes, whereas tegument
and vitelline cells were much less affected. MFQ was the most
destructive drug, especially on vitelline cells. Upon treatment with
PA1259, the more specific effect was a drastic decrease in
hemozoin content, along with damages on the tegument and
vitelline cells. The damages induced by artemether were much less
severe and focalized on the tegument surface. This suggests certain
specificity in the mode of action of each compound. The hybrid
structure of trioxaquine PA1259 should explain interaction with
heme polymerization, due to the 1,2,4-trioxane ring, and a severe
effect on the musculature and tegument, as shown with the
quinolone-based MFQ.
5. Molecular mechanism of damages induced by
antischistosomal drugs
a. Reduced or radical oxygen species: NON,O 2N
2,
H2O2. Quantification of ROS was performed on adult worms
at a drug concentration giving the same proportion of immobilized
worms, for PZQ and PA1259 [28a]. Results are reported in
Figure 8. In worms treated with PZQ, the production of O2N
2 was
twice higher than that of control worms. By contrast, treatment
with PA1259 did not improve the production of O2N
2 with respect
to control (Figure 8A). The production of H2O2 production
whether control, PZQ, or PA1259 was similar (Figure 8B). The
most significant feature was NON production, which was very
low in control worms. Females treated with PZQ exhibited a
slightly enhanced production of NON (61.5) near the tegument,
whereas, in females treated with PA1259, the fluorescence due
to NON was very high (64.3 with respect to control worms) and
mainly detected inside the gut and near the vitelline cells
(Figure 8C). Then, the reactive oxygen species produced are
different, in nature, in localization, and in quantities, when
worms are treated with either PZQ or PA1259. These results
strongly suggest that these drugs have different targets and
mechanisms of action on schistosomes. Oxadiazoles may also act
as nitric oxide donors [6b]. Quantification of gene transcripts
showed that anti-oxidant metabolism is increased when worms
are exposed to a sub-lethal dose of PZQ. Our results are
consistent with reference 47.
b. Characterization of covalent heme-drug adducts. The
alkylation ability of the drug toward heme was investigated in S.
mansoni treated with ARTM or PA1259. In both cases, heme-
drug adducts were detected by LC-MS analysis of the worm
extracts.
In the extract of worms treated by ARTM (Figure 9), the
product having ionic current m/z=854.4 amu is consistent with
the formation of heme-artemether covalent adducts 2 depicted in
Figure 11. The reductive activation of the O–O bond of
artemether by iron(II)-heme, followed by homolytic cleavage of
the C3–C4 bond, resulted in the formation of a primary alkyl
radical centered at C4. As previously reported with the heme
model manganese(II)-tetraphenylporphyrin, this radical was able
to alkylate the porphyrin macrocycle, leading to covalent heme-
drug adducts [48]. As for artemisinin, alkylation of heme by the
drug can indeed occur on the four meso positions of the porphyrin
macrocycle, giving rise to regioisomeric adducts 1. The ‘‘South’’
cycle of the artemether moiety was subsequently rearranged by
nucleophilic attack of the hydroxyl function at C12a onto the
acetal C10, to generate the heme-artemether adduct 2, bearing a
5-membered lactone. Such a mechanism is very similar to the
rearrangement reported for artemisinin derivatives having an
amine function at C10 [49]. Trace amounts of ‘‘complete’’
covalent heme-artemether adducts 1 (Me=914.4 amu), were also
detected, with m/z=936.4 amu, corresponding to the substitution
of a proton of a propionic side chain of heme by sodium [(M-
H+Na)
+].
The LC-MS analyses of extracts of S. mansoni worms treated
with PA1259 are reported in Figure 10a–c. The exact mass value
of 1101.2 amu (Figure 10b) corresponds to the mass of heme
(616.2) plus the mass of PA1259 (485.2), and can be assigned to
Figure 11. Mechanism of alkylation of heme by artemether (the oval stands for the protoporphyrin-IX ligand).
doi:10.1371/journal.pntd.0001474.g011
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mechanisms of formation of these adducts are depicted in
Figure 12. It should be noted that the inner-sphere reductive
activation of the peroxide bond of PA1259 can occur with
coordination of iron(II)-heme either on O1 or O2, giving rise to
the formation of alkoxy radicals either on O2 or O1, respectively.
Subsequent b-scission of the adjacent C3–C11 or C6–C7 bond,
respectively, generated C-centered radicals able to alkylate heme
and provide the covalent heme-drug adducts 3 and 4. The
covalent adduct 5, resulting from the hydrolysis of the hemiacetal
function of adduct 4, was also detected (Figure 10c). In addition,
the isotopic patterns of signals at m/z 551.3 and 730.3 clearly
showed that the corresponding adducts contained one iron atom
(M-1 at 550.3 and M-2 at 728.2, respectively, due to
54Fe). By
contrast, one chlorine atom was detected in adducts at m/z 551.3
(M+1 at 552.3 due to
37Cl), whereas adduct 5 contained no
chlorine after release of the 79-chloro-49-aminoquinoline moiety
(Figure 12). The heme-drug adducts 2–5 were undetectable in all
extracts of untreated S. mansoni worms. Because the worms treated
with ARTM or PA1259 were carefully washed before lyophiliza-
tion, the detected adducts were clearly contained inside the worms,
and cannot be considered as an external contamination.
c. Heme oxidative cleavage in S. mansoni. Ah e m e
oxidase activity has been previously reported in S. japonicum [50],
which may account to supply iron to schistosomes by catabolism
of the heme of the host. Then, we were interested to detect heme
fragments that might result from the possible oxidative cleavage
of the heme macrocycle by the parasites. The LC-MS analysis of
untreated worms showed the presence of two chromatographic
peaks with the same m/z value of 347.1 amu. These peaks were
also produced (with same mass spectrum and retention time
values) by reaction of hemin or b-hematin, the synthetic analogue
of hemozoin, in the presence of hydrogen peroxide [El Rez,
Pradines and Robert, unpublished data]. The mass and UV
absorption (lm=280 nm) of these heme fragments suggest a
common dipyrrolic structure. Possible structures are depicted in
Figure 13, which result from oxidative cleavage of C5–C6, C7–
C8, and C15–C16 (6a), C5–C6, C15–C16, and C17–C18 (6b),
or C10–C11 and C19–C20 (6c) of heme ligand, in a similar way
as the cleavage protoporphyrin-IX to biliverdin-IX by
mammalian heme oxygenases. Obviously, the cleavage of the
heme ring results in a drastic loss of visible absorbance, and
discoloration of the pigment. Interestingly, treatment with
ARTM or MFQ did not produce a significant amount of that
heme fragment.
Conclusion
A multidisciplinary approach allowed us to propose the
following mode of action of the antischistosomal trioxaquine
PA1259. First, the easy absorption due to the quinoline moiety of
PA1259 should allow the drug to interact with the schistosome
process of polymerization of heme to hemozoin. The reaction of
the peroxide function of trioxaquine with free heme resulting from
the degradation of hemoglobin was assessed by the production of
heme-drug adducts characterized in worm extracts. As heme-drug
adducts are probably able to inhibit the heme polymerization, and
are themselves unable to polymerize (this feature has been
demonstrated for heme-artemisinin adducts [51]), this reaction
Figure 12. Mechanism of alkylation of heme by trioxaquine PA1259 (the oval stands for the protoporphyrin-IX ligand).
doi:10.1371/journal.pntd.0001474.g012
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derivatives. Then, the iron chelated by the protoporphyrin-IX
ligand of heme or heme-drug adducts induced the production of
reactive oxygen species, which should readily destroy hemozoin by
radical chain reactions, resulting in (i) drastic discoloration of
worms from black to brown, and (ii) much lower density of
hemozoin in worms treated with PA1259 than in control worms,
as observed in microscopy (Figures 3 and 6).
The high quantity of nitric oxide detected in the parasite gut is
certainly an important element of this oxidative stress (Figure 8).
Third, this oxidative stress would cause gastrodermis perforation
and the passage of the gut content through the gastrodermis, as
observed by electronic microscopy (Figure 6). The oxidative
cleavage of heme also releases free iron that should increase the
production of radical oxygen species. Finally, the substructure of
the tegument was altered by the invasion of oxygen reactive
species (Figures 4 and 7).
However, several questions remain to be adressed. Indeed, the
fact that cercariae are heavily affected by treatment, the external
tegumental alteration, and the effect on vitelline cells observed
with PA1259 are not directly explained by reaction of the drug
with heme. But the sequence hemoglobin/heme/hemozoin is not
the single source of iron in schistosomes and several other iron
proteins may play a role. Schistosomes have high demand for iron
and are dependent on host iron for early development within the
mammalian host [52]. In each stage, from miracidia to adult,
schistosomes express tegumental divalent metal transporters
involved in iron uptake [53]. Moreover, schistosomes are known
to bind host transferrin at their surface [52]. The parasite also
possesses two ferritin isoforms involved in storage and release of
iron [54,55]. One isoform, called yolk-ferritin or ferritin 1, is
predominantly found in mature egg laying female, where it has
been localized in the vitelline cells and in the ovary [56]. Vitelline
stores of iron are implicated in eggshell formation [57].
Interestingly, the two isoforms of ferritin are also expressed in
the parasite egg suggesting these molecules are also synthesized by
embryo [57]. These observations emphasize the importance of
iron in schistosome metabolism and egg formation, even on worm
stages that do not ingest hemoglobin yet. Ferritin has not yet been
characterized in cercariae, however the expressed sequence tags of
ferritin 2 are available in sequence database suggesting that
cercariae express this enzyme. Several recent articles suggest that
iron metabolism should be a valuable target for either chemo-
therapy or vaccine development against schistosomes [58,59].
Using an anti-schistosomal drug that is also active on malaria
parasites is a real matter of discussion [PA1259 is curative on P.
vinckei petteri infected mice orally treated at 25 mg/kg/day during
four days (5/5 mice cured without recrudescence at Day-30,
unpublished data from Palumed)]. Such dual activity might be
considered as an advantage since patients are suffering from both
diseases in many endemic areas. One the other side, one can argue
about the possibility to generate trioxane-resistant strains of P.
falciparum. But we should keep in mind that no trioxaquine-
resistant strain has been selected after two years of drug pressure
(unpublished results).
In conclusion, trioxaquine PA1259 is the most active against
schistosomes among the trioxane-containing drugs that have been
tested up to now. Its phosphate salt, PA1647 acts in synergy with
praziquantel, specially against schistosomules, when infected mice
are treated by oral administration. This opens the route to an
efficient bitherapy of a highly neglected disease.
Supporting Information
Figure S1 SEM images of S. mansoni adult females.
Control worms (a), compared to worms treated with b)
praziquantel (PZQ), c) trioxaquine PA1259, d) mefloquine
(MFQ), or e) artemether (ARTM). White crosses are breaks
related to the preparation for microscopy.
(TIF)
Figure S2 SEM images of the dorsal face of the head
region of S. mansoni adult females. Control worms (a),
compared to worms treated with b) praziquantel (PZQ), c)
trioxaquine PA1259, d) mefloquine (MFQ), or e) artemether
(ARTM). Magnification 65000; the bars stand for 1 mm. Sensory
papillae are noted sp. Crystals caused by buffer are noted buf.
(TIF)
Figure S3 SEM images of the mid-body region of S.
mansoni adult females. Control worms (a), compared to
worms treated with b) praziquantel (PZQ), c) trioxaquine PA1259,
d) mefloquine (MFQ), or e) artemether (ARTM). Magnification
65000; the scale bars stand for 1 mm.
(TIF)
Figure S4 SEM images of the mid-body region of S.
mansoni adult females. Control worms (a), compared to
worms treated with b) praziquantel (PZQ), c) trioxaquine PA1259,
d) mefloquine (MFQ), or e) artemether (ARTM). Magnification
61000; the scale bars stand for 10 mm.
(TIF)
Figure S5 SEM images of tegumental damages in S.
mansoni adult females. Worms treated with a) trioxaquine
PA1259, or b) artemether (ARTM) (tail region). Magnification
62000 (a1,b1) or 65000 (a2,b2); the scale bars stand for 10 mm
(a1-b1), or for 1 mm (a2-b2).
(TIF)
Figure S6 TEM images of vitelline cells (vc) containing
vitelline balls (vb). Control worms (a), compared to worms
treated with b) praziquantel (PZQ), c) trioxaquine PA1259, d)
mefloquine (MFQ), or e) artemether (ARTM). The scale bars
stand for 1 mm in panels a1-e1, and 2 mm in panels a2-e2. Fusion
of vitelline balls (vb) in vitelline droplets (vd); ld stands for lipid
droplets.
(TIF)
Figure S7 SEM images of the tail region of S. mansoni
adult females. Control worms (a), compared to worms treated
with b) trioxaquine PA1259. Magnification 62000 (a1, b1) or
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